Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Wiley 2020-07-01
סדרה:	Endocrinology, Diabetes & Metabolism
נושאים:	albuminuria CCR2 diabetes kidney MCP‐1 propagermanium
גישה מקוונת:	https://doi.org/10.1002/edm2.159
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!